Background: Evidence supporting sodium-glucose cotransporter-2 (SGLT2) inhibitor use in stage 5 chronic kidney disease (CKD) remains limited because major randomized trials have largely excluded this population. We evaluated associations between SGLT2 inhibitor use and cardiovascular and kidney outcomes in patients with stage 5 CKD. Methods: We systematically searched PubMed, Scopus, Cochrane CENTRAL, and Google Scholar through April 10, 2026.